News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2019

16 October, 2019 PledPharma approved for listing on Nasdaq Stockholm News Corporate Action Other English Regulatory MAR IR Optional
9 October, 2019 PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-pledox
21 August, 2019 Half-Year report January-June 2019 News English Regulatory MAR Report Interim Q2 IR Optional
15 July, 2019 The Lancet EBioMedicine publishes Aladote® study results News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
11 July, 2019 Aladote® – regulatory interactions News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote
31 May, 2019 PledPharma presents PledOx®’s global phase III program at ASCO News Corporate Information Presentation English IR Optional mfn-cus-pledox
21 May, 2019 PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
21 May, 2019 PledPharma announces intention of a Directed New Share Issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
7 May, 2019 Report from the Annual General Meeting of PledPharma News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
6 May, 2019 Interim report January-March 2019 News English Regulatory MAR Report Interim Q1 IR Optional
12 April, 2019 PledPharma's drug candidate Aladote® is highlighted at one of the largest liver conferences globally News Corporate Action Other English IR Optional mfn-cus-aladote
8 April, 2019 NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
8 April, 2019 PledPharma’s 2018 annual report published News English Regulatory Listing Regulation Report Annual IR Optional
26 March, 2019 Data from the POP study support further development of Aladote® as a new treatment option for reducing liver damage due to paracetamol overdose News Corporate Information Presentation English IR Optional mfn-cus-aladote
26 March, 2019 PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm News Corporate Information Presentation English IR Optional
18 March, 2019 PledPharma’s drug candidate Aladote® granted Orphan Drug Designation News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-aladote
14 March, 2019 PledPharma Capital Markets Day, March 26 News Corporate Action Other English IR Optional
21 February, 2019 Year-end Report January-December 2018 News English Regulatory MAR Report Interim Yearend IR Optional mfn-cus-aladote mfn-cus-pledox
5 February, 2019 PledPharma Capital Markets Day News Corporate Information Presentation English IR Optional
31 January, 2019 Aladote®’s data has been selected for presentation at The International Liver Congress News English Regulatory IR Optional
17 January, 2019 PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium News English Regulatory IR Optional
10 January, 2019 First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma News English Regulatory IR Optional

2018

24 December, 2018 PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote News English Regulatory IR Optional
13 December, 2018 PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference News English Regulatory IR Optional
5 December, 2018 PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 News English Regulatory IR Optional
PreviousNext

Calendar and upcoming reports

August 22, 2024
Interim Report Q2 2024 (7:00am CEST)

September 19, 2024
Pareto Annual Healthcare Conference

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all